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Myeloid cells are a heterogeneous population of bone marrow-derived cells that play a critical role during growth and metastasis of
malignant tumors. Tumors exhibit signiﬁcant myeloid cell inﬁltrates, which are actively recruited to the tumor microenvironment.
Myeloid cells promote tumor growth by stimulating tumor angiogenesis, suppressing tumor immunity, and promoting metastasis
to distinct sites. In this review, we discuss the role of myeloid cells in promoting tumor angiogenesis. Furthermore, we describe a
subset of myeloid cells with immunosuppressive activity (known as myeloid-derived suppressor cells). Finally, we will comment
on the mechanisms regulating myeloid cell recruitment to the tumor microenvironment and on the potential of myeloid cells as
new targets for cancer therapy.
1.Introduction
Angiogenesis, the growth of new blood vessels, occurs at
diﬀerent stages during embryonic development, physiolog-
ical processes such as wound healing and reproduction, and
numerous diseases, including inﬂammation, tumor progres-
sion, and metastasis [1]. The human immune system is com-
posed of an innate and an adaptive branch. They both play
a key role in maintaining homeostasis within our organism.
The innate immune system is mainly composed of myeloid
lineage cells, such as macrophages, neutrophils, and mast
cells [2]. Under nontumor conditions, these cells provide
the ﬁrst line of protection against pathogens. Importantly,
during tumor progression, myeloid cells are implicated in
promoting tumor angiogenesis, causing resistance against
antiangiogenic therapies in cancer, and suppressing the
immune response during cancer [3–5].
2. Angiogenesisand Vasculogenesis during
Tumor Growth
2.1. Angiogenesis. Neovascularization, the formation of
new blood vessels, plays important roles in development,
inﬂammation, and wound repair. Mammalian cells require
oxygen and nutrients for their survival and are therefore
located within 100 to 200 μm of blood vessels, the diﬀusion
limit of oxygen. In 1971, Dr. Judah Folkman observed that
neovascularization occurs around tumors and proposed that
new blood vessel growth is necessary to supply nutrients and
oxygen to tumor cells during exponential tumor growth [6].
These observations stimulated an intensive search for the
mechanisms regulating tumor angiogenesis. It is now known
that new blood vessels originate from preexisting vessels
by activation, proliferation and migration of endothelial
cells through a process named “angiogenesis” [4]. Speciﬁc
growth factors, such as vascular endothelial growth factor
(VEGF) and basic ﬁbroblast growth factor (bFGF), stimu-
late the proliferation and migration of naturally quiescent
endothelial cells, resulting in the formation of new ves-
sel structures during embryonic development and tumor
growth [7]. Although tumor cells were ﬁrst thought to drive
the cellular events underpinning tumor angiogenesis and
growth, considerable evidence has now emerged for the
central role of tumor inﬁltrating myeloid cells such as mono-
cytes, macrophages, and neutrophils in this phenomenon
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2.2. Vasculogenesis. Vasculogenesis is the coalescence of
new blood vessels from individual endothelial cells or
progenitor cells. Until recently, vasculogenesis was thought
to be restricted to the formation of the initial vascular
tree during embryonic vascular development. In 1997,
Asahara et al., [13] isolated mononuclear cells from human
peripheral blood that were enriched for expression of the
hematopoietic stem cell marker CD34 [13]. Upon culture in
endothelial growth media, these cells expressed endothelial
lineage markers, such as CD31, Tie2, and VEGF receptor 2
(VEGFR2), and incorporated into blood vessels in ischemic
tissues. These cells were therefore described as bone marrow
derived endothelial progenitor cells (EPCs). Subsequent
studiesdescribedaVEGFR2andAC133expressingsubpopu-
lationoftheseCD34positivecirculatingcellsthatcouldform
endothelial colonies in vitro [14, 15]. This suggested that
EPCs are able to diﬀerentiate into endothelial cells and that
such cells are incorporated into sites of active angiogenesis
including ischemia, tumor angiogenesis, and metastasis in
adult organisms [16, 17]. Since then, the study of circulating
EPCs has generated considerable interest and controversy.
Diﬀerent markers, methods, and diﬀerent kinds of cancer
models used to identify EPC probably contributed to the
widelydivergentreportsofthelevelofincorporation ofthese
cells into newly formed tumor blood vessels [5]. These levels
ranged from highs of 20% to 50% to lows of 5% or even less,
the lower levels being more common [18–20].
3. M1 andM2 Tumor AssociatedMacrophages
3.1. Classical and Alternative Activation. Monocytes and
macrophages belong to the myeloid cell lineage and derive
from myeloid progenitor cells. These precursor cells are
located in the bone marrow; upon maturation, mono-
cytes are released into the bloodstream. Circulating blood
monocytes migrate into tissues where they diﬀerentiate into
resident tissue macrophages.
Macrophages are activated in response to environmental
signals, including microbial products and cytokines. Acti-
vated macrophages can be divided into M1 (classical acti-
vated) and M2 (alternative activated) phenotype (Figure 1)
[21]. Classical activation occurs in response to bacterial
moieties such as lipopolysacharide (LPS) and immune stim-
uli such as interferon-γ (IFN-γ). M1 macrophages mediate
resistanceagainstintracellularparasitesandtumorsandelicit
tissue disruptive reactions by secreting tumoricidal agents
such as tumor necrosis factor α (TNF-α), interleukin-12
(IL-12), reactive nitrogen (iNOS), and oxygen intermediates
(ROS). In addition, M1 macrophages promote T-helper-1
(Th1) responses. By contrast, M2 activated macrophages
come in diﬀerent varieties depending on the eliciting sig-
nals, which include IL-4, IL-13, IL-10, and glucocorticoid
hormones. In general, M2 macrophages have an immune
suppressive phenotype and release cytokines including IL-10
thatpromoteaTh2immuneresponse[22–24].Macrophages
in tumors—usually termed tumor-associated macrophages
(TAMs)—often express the M2 phenotype. However, recent
evidence suggested that the phenotype of TAM varies with
the stage of tumor progression. M1 macrophages are often
abundant in chronic inﬂammatory sites, where tumors are
initiated and start to develop. Then the macrophages switch
to an M2-like phenotype as the tumor begins to invade,
vascularize, and develop [25].
3.2. Proangiogenic Phenotype. M2-like TAMs release a num-
ber of potent proangiogenic cytokines, such as VEGF-A,
VEGF-C,TNF-α,IL-8,andbFGF[26,27].Additionally,these
TAMs also express a broad array of proteases known to
play roles in the angiogenic process. These proteases include
urokinase-type plasminogen activator (uPA), the matrix
metalloproteinases MMP-2, MMP-7, MMP-9, and MMP-12,
and elastase [28, 29]. uPA and MMP support angiogenesis
by remodeling and breaking down the extracellular matrix
(ECM). Degradation of ECM leads to the mobilization of
growth factors and facilitates the migration of vascular cells
into new environments [30–32]. Strong correlations are
observed between TAM densities and vascular densities in
many human tumor types, suggesting that TAMs regulate
neovascularization. Importantly, high TAM densities are
indicative of poor prognoses in breast, prostate, ovarian, and
cervical cancers [33–35].
4.MyeloidDerivedSuppressorCells
4.1. Heterogeneous Family. Besides promoting angiogenesis,
a subset of myeloid cells can facilitate tumor growth by
their ability to downregulate the immune response against
cancer cells. These so-called myeloid derived suppressor
cells (MDSCs) are a heterogeneous population of cells that
consist of myeloid progenitor cells and immature myeloid
cells (IMCs). In healthy individuals, IMCs are generated in
the bone marrow. They quickly diﬀerentiate into mature
granulocytes, macrophages, or dendritic cells (DCs). In
contrast, in pathological conditions such as cancer, a partial
b l o c ki nt h ed i ﬀerentiation of IMCs into mature myeloid
cells occurs, which results in the expansion of the MDSC
population. MDSCs can be found in the bone marrow (BM),
spleen, and tumor sites and have been identiﬁed in most
patients and in experimental mice with tumors based on
their ability to suppress T cell activation [36].
MDSCs lack the expression of cell surface markers that
are speciﬁcally expressed on monocytes, macrophages, or
DC. In mice MDSCs are uniformly characterized by the
expression of the cell surface molecules detected by antibod-
ies to Gr1 and CD11b. Gr1 includes the macrophage and
neutrophil markers Ly6C and Ly6G, respectively, whereas
CD11b (also known as integrin αM) is characteristic for the
myeloid-cell lineage. In recent years, several other surface
molecules have been used to identify additional subset
of suppressive MDSC, including CD80 [37], CD115 (also
known as macrophage colony-stimulating factor (M-CSF)
receptor, and CD124 (IL-4 receptor alpha chain (IL-4Ra))
[38].
In addition, nuclear morphology has also been used
to characterize mouse MDSC. MDSCs that are
mononuclear are considered “monocytic” and are
typically CD11b
+Ly6G+/−Ly6Chigh, whereas those withJournal of Oncology 3
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Figure 1: Cytokines produced in the tumor microenvironment can give rise to macrophages with distinct physiologies. Classical activated
macrophages (M1) arise in response to interferon γ (IFN-γ). M1 macrophages elicit tissue disruptive reactions by producing tumor necrosis
factor α (TNF-α), interleukin 12 (IL-12), reactive nitrogen, and oxygen intermediates. M1-activated macrophages are part of the polarized
Th1 response. M2 macrophages are generated in response to various stimuli, including IL-4, IL-13, IL-10, and glucocorticoids. Tumor-
associated macrophages have properties of M2-activated cells. They express many proangiogenic and angiogenic modulatory factors such
as IL-1β, IL-6, IL-8, vascular endothelial growth factors (VEGFs), and matrix metalloproteinases (MMPs). M2 macrophages are part of the
Th2 response.
multilobed nuclei are “granulocytic/neutrophil-like” and are
CD11b
+Ly6G+Ly6C
− [39, 40].
In cancer patients MDSCs are typically deﬁned as
CD11b
+CD14neg, cells that express the common myeloid
marker CD33 but lack the expression of markers of mature
myeloid and lymphoid cells, and of the MHC class II
molecule HLA-DR [41, 42]. In addition MDSCs have also
been identiﬁed within a CD15+ population in human
peripheral blood [43].
4.2. Mechanism of Immune Suppression by MDSC. Several
mechanisms have been associated with the immunosup-
pressive eﬀects of myeloid cells, including secretion of
immunosuppressive cytokines, upregulation of nitric oxide
(NO), generation of ROS, and increased activity of L-
arginase [44].
Arginase, iNOS, ROS, and COX2: L-arginine plays a critical
role in the immunosuppressive activity of MDSC. T-cell
proliferation and activation depends on the availability of
L-arginine. L-arginine is a nonessential amino acid and is a
substrate for two enzymes, inducible NO synthase (iNOS or
NOS2) and arginase 1. MDSCs express both enzymes at high
levels [36]. Recent data suggests that the increased activity of
arginase 1 and iNOS in MDSC leads to enhanced L-arginine
catabolism, which results in a reduction or depletion of L-
arginine in the microenvironment. The lack of L-arginine
results in inhibition of T-cell function [41, 45].
MDSC-produced ROS inhibits CD8+ Tc e l lb yc a t a l y z -
ing the nitration of the TCR and thereby preventing T
cell peptide-MHC interactions [46]. In addition, several
k n o w nt u m o r - d e r i v e df a c t o r s ,s u c ha sT G F - β, IL-3, IL-6,
IL-10, platelet-derived growth factor (PDGF), and granulo-
cyte macrophage colony stimulating factor (GM-CSF), can
induce the production of ROS by MDSC [36, 47].
Cyclooxygenase-2(COX2)isakeyfactorintheactivation
of MDSC, because it regulates the expression of arginase
1, iNOS and prostaglandin E2 (PGE2). PGE2 and COX2
are produced by many tumors and are major contributors
to the inﬂammatory milieu [48]. PGE2 was also shown to
upregulate CD11b
+CD14
−CD15+ MDSC in patients with
renal cancer [41]. Therefore, elevated PGE2 levels were
associated with higher levels and more suppressive MDSC.
COX2 inhibitors have proven clinical applications for the
treatment of colon cancer and intestinal polyposis [49].
Cytokines: MDSC-derived cytokines can suppress antitumor
immunity. Secretion of the type 2 cytokine IL-10 down-
regulates the production of the type 1 cytokine IL-12 in
macrophages. In addition, IL-10 and VEGF inhibit the
maturation of DC [50]. TGF-β has also been associated with
MDSC immune suppressive functions. In ﬁbrosarcoma and
colon carcinoma tumor models, MDSC produced TGF-β in
response to IL-13 stimulation, which resulted in decreased
tumor immunosurveillance of cytotoxic T-cells [51, 52].
5.VariousProtumorigenicMyeloid
Subpopulations
In recent times, most studies have analyzed the role that
TAM and MDSC have on tumor angiogenesis and pro-
gression. However, there is now increasing evidence to
show that various other myeloid subpopulations, such as
Tie2 expressing monocytes, neutrophils, eosinophils, mast4 Journal of Oncology
cells, and dendritic cells, also actively participate in these
processes. In this paragraph we brieﬂy discuss the likely
mechanisms by which these cells driving tumor angiogenesis
and progression.
5.1. Tie2 Expressing Monocytes. De Palma et al., [53] recently
identiﬁed a distinct lineage of myeloid cells that can be
distinguished from other monocytes by their expression
of the angiopoietin receptor Tie2 [53]. Although Tie2 is
broadly expressed on vascular endothelial cells and gen-
erally regarded as an EC speciﬁc marker, Tie2 expressing
monocytes (TEMs) are distinct from ECs and do not
incorporate in the tumor endothelium. TEMs are a small
monocyte subset that circulate in the mouse and human
peripheral blood and appear to be preferentially recruited
to tumors and other sites of angiogenesis [53]. In mouse
blood, TEMs express CD45, the pan leukocyte marker, and
CD11b, but do not express Gr1 (Ly6G/C), which is detected
on granulocytes, DC, and MDSC. TEMs are a subset of
tumor inﬁltrating F4/80+ macrophages. In distinct tumor
areas, TEM may account up to 30% of the total F4/80
macrophages [54, 55]. The close proximity of some TEMs to
the tumor vasculature suggested to De Palma and colleagues
that these cells might contribute to the regulation of tumor
angiogenesis. The speciﬁc elimination of TEM by suicide
gene strategy in mouse tumor models inhibited tumor
angiogenesis. Interestingly, ablation of TEM did not aﬀect
the recruitment of TAM or neutrophils into these tumors,
suggesting that, rather than being precursors of TAM, TEMs
comprise a distinct monocyte subpopulation with potent
proangiogenic activity. However, it is not clear whether TEM
and TAM derive from a common monocytic precursor, or
whethertumormicroenvironmentalfactorscaninduceTAM
to acquire a “TEM phenotype” or vice versa. It was suggested
that TEMs stimulate angiogenesis by expressing the potent
proangiogenic moleculebFGF (althoughtheactualreleaseof
this growth factors has yet to be demonstrated) [53].
5.2. Neutrophils. Neutrophils are phagocytic, polymor-
phonuclear cells and are the most abundant subpopulation
of leukocytes in the blood and are principally involved in
acute inﬂammatory response to invading microorganisms.
Increases levels of neutrophils have been observed in patients
with gastric, colon, and lung cancer [56, 57]. In humans,
neutrohilscanbeidentiﬁedbythecellsurfacemarkerCD66b
(also known as CEACAM8), or by the cytoplasmic marker
myeloperoxidase (MPO) coupled with cell morphology. In
murine tumors, Gr1+ cells are usually considered to be
neutrophils or cells derived from neutrophil precursors.
However,itshouldbenotedthatmurineMDSCsalsoexpress
Gr1+ [36].
The mechanism by which tumor-associated neutrophils
mediate or modulate tumor angiogenesis has not been
fully elucidated. Tumor-associated neutrophils are a major
source of MMP9 (along with macrophages and mast cells)
in various murine tumor models and so could promote
angiogensis by releasing potent angiogenic factors such as
VEGF that are usually sequestered in the ECM [58]. In
addition, TNFα-stimulated neutrophils undergo degranula-
tion and thereby releasing their intracellular VEGF storage,
which subsequently induces endothelial cell proliferation
and tube formation in vitro [59]. Recently Fridlender et
al. [11] described that tumor-associated neutrophils (TANs)
can be polarized in the tumor microenvironment into
N1 and N2 phenotype similar as described previously for
tumor-associated macrophages. Thereby, within the tumor
microenvironment, TGF-β induced and maintained a popu-
lation of TAN with an N2 tumor-promoting phenotype.
5.3. Eosinophils. Eosinophils are characterized by the expres-
sion of CCR3 and CD125. They are multifunctional leuko-
cytes implicated in the pathogenesis of numerous inﬂam-
matory processes including parasitic helminths infections
and allergic diseases [60]. Increased numbers of eosinophils
have been reported for several human tumors including oral
squamous cell carcinoma, gastrointestinal tumors, Hodgkin
lymphoma, and nasopharyngeal carcinoma [61–64]. The
highly potent and selective eosinophil chemoattractant
CCL11 (eotaxin), which binds to CCR3, was described
to mediate the recruitment of eosinophils to the tumor
microenvironment [65]. The role of eosinophils in the
tumor microenvironment remains unclear. Accumulation of
eosinophils in the necrotic region suggests that eosinophils
may promote necrosis and might have antitumor activ-
ity [66]. Alternatively, there is evidence to suggest that
eosinophils recruited to tumor sites can inﬂuence angiogen-
esis. Eosinophils contain VEGF in their secretory granules,
which are rapidly secreted upon activation with IL-15 [67].
In addition, TNFα-stimulated eosinophils release proangio-
genic factors like bFGF, IL-6, IL-8, PDGF, and MMP9 [68].
However, the release of proangiogenic factors of IL-15 and
TNFα-stimulatedeosinophilshasonlybeenobservedinvitro
and has yet to be conﬁrmed in tumors.
5.4. Mast Cells. Mature mast cells (MCs) populate most
tissues but are found in highest numbers in the skin,
airways, and digestive tract, where they are thought to act
as a ﬁrst line of defense against inﬁltrating pathogens and
parasites. MCs also have an important role in generating and
maintaining innate and adaptive immune responses as well
as the development of autoimmune disorders and tolerance.
MCs are usually identiﬁed by basic Giemsa or toluidine blue
staining, expression of cell surface markers such as C-kit
receptor (CD117) in human and CD34 in mice, or stored
cytoplasmic molecules including tryptase and chymase [69].
MC originate from the bone marrow as immature cells and
migrate to peripheral tissues where they mature in situ.
Mast cells are now recognized as an early and persistent
inﬁltrating cell type in many tumors, often entering before
signiﬁcant tumor growth and angiogenesis occurred. Mast
cells accumulate at the boundary between healthy tissues
and malignancies and are often found in close association
with blood vessels within the tumor microenvironment.
TheyexpressmanyproangiogeniccompoundssuchasVEGF,
bFGF, MMP9, TGF-β,T N F α, and IL-8. In several human
tumors increased MC density positively correlates withJournal of Oncology 5
increased microvessel density and in some cases, with poor
prognosis [70].
5.5. Dendritic Cells. Dendritic cells (DCs) are specialized
antigen presenting cells that acquire, process, and present
tumor-associated antigens to T-cells for the induction
of antigen-speciﬁc tumor immune response. Two distinct
populations of DC exit in mouse and human tissues: (i)
myeloid DC (MDC) and (ii) plasmacytoid DC (PDC).
MDCs express CD11c and CD33 and lack CD45R, CD123,
and Lin, whereas PDCs are CD123+, CD45R+,C D 4 +,
CD11c
−,I L T 3 +,I L T 1
−,a n dL i n
− [71]. MDCs originate in
the bone marrow as immature cells (iDC) that lack the
classical mature DC markers, CD1a, CD83, CD40, and
CD86. Once they process foreign antigen, they become
activated, undergo maturation, and migrate to lymphoid
tissuewheretheyinitiateactivationofantigen-speciﬁcTcells
[72].
By their potential capacity to activate tumor-speciﬁc T-
cellresponses,DCplayanimportantroleincancerimmuno-
surveillance. Interestingly, circulating and tumor-inﬁltrating
DCs from cancer patients appear to be phenotypically and
functionally defective. Several tumor-derived factors have
been shown to be responsible for systemic and local DC
defects [73]. Beside the vast majority of reports of MDC
in cancer focusing on their suppressed immunoregulatory
function, it has become apparent that iDCs also promote
tumor neovascularization. For example, Conejo-Garcia and
colleagues [74] described a mechanism of tumor vascu-
logensis mediated by DC precursors. β-defensin mediated
recruited of DC precursors to tumors enhanced tumor vas-
cularization and growth in the presence of increased VEGF-
A expression. Thereby VEGF-A induced the simultaneous
expression of both, endothelial and DC markers, on DC
precursors and the DC precursors underwent endothelial-
like specialization. These cells were termed vascular leuko-
cytes (VLCs) and are highly present in human ovarian carci-
nomas. Depending on the milieu, VLCs can assemble into
functional blood vessels or act as antigen-presenting cells
[75].
A recent report underlined the important role of imma-
ture DC during tumor vascularization [76]. In this study
only tumor cells implanted with immature DC, but not
with mature DC, revealed increased neovascularization and
growth. In addition, complete depletion of DC in a trans-
genic CD11c+DTR-Tg mice model abrogated angiogenesis
in bFGF loaded Matrigels and inhibited the growth of
intraperitoneally injected B16 melanoma cells (although the
tumor model used in this study is uncommon).
Beside the role of immature DC/VLC in vasculogenesis,
immature DC might also promote angiogenesis. A recent
report showed that human iDCs upregulate proangiogenic
cytokines such as VEGF and IL-8 on exposure to severe
hypoxia in vitro [77]. Beside their proangiogenic role, VEGF
and IL-8 are also immunosuppressive cytokines capable to
inhibit DC maturation and so might act in an autocrine as
well as a proangiogenic manner if released by immature DC
in hypoxic tumor sites.
6.MyeloidCellMediateResistanceto
AntiangiogenicDrugs
Recently, Shojaei et al. [78] reported that accumulation
of CD11b+Gr1+ c e l l si nt u m o r sr e n d e r st h e i rr e f r a c t o r y
to anti-angiogenic blockage by VEGF antibodies. Diﬀerent
murine tumor cell lines were tested for their responsiveness
to anti-VEGF antibody treatment. Refractory tumors were
associatedwithsigniﬁcantincreaseinthefrequencyoftumor
inﬁltrating CD11b+Gr1+ cells compared to sensitive tumors.
Moreover, when normally sensitive tumor cells were mixed
with these cells that are resistant to anti-VEGF antibodies
and transplanted into other mice, the transplanted tumors
resist anti-VEGF antibodies. In contrast, CD11b+Gr1+ cells
isolated from sensitive tumors were unable to mediate
refractoriness to anti-VEGF treatment, indicating that the
tumor directly modulates CD11b+Gr1+ cells to promote
angiogenesis independent of VEGF. Gene array analysis
revealed an upregulation of G-CSF and monocyte chemo-
tactic protein 1 (MCP-1) in resistant tumors, both factors
known to be involved in the mobilization of bone marrow
derived myeloid cells to the peripheral blood. In addition,
proinﬂammatory factors such as macrophage inﬂamma-
tory protein 2 (MIP-2), IL-1 inducible protein, and IL-1β
were also upregulated in resistant tumors, while resistant-
mediating CD11b+Gr1+ cells revealed increased expression
of proinﬂammatory cytokine receptors such as IL-1, IL-4,
IL-11, and IL-13. Taken together, these ﬁndings suggest that
inﬂammation is an important aspect of tumor refractoriness
in response to anti-VEGF antibody treatment.
Fischer et al., [79] described the use of neutralizing
murine antiplacental growth factor (PlGF) monoclonal
antibody [79]. Anti-PlGF antibody inhibited growth and
metastasis of various tumors, including those resistant
to VEGF-receptor 2 (VEGFR2) inhibitors. In contrast to
anti-VEGFR2 treatment, anti-PlGF prevented inﬁltration of
angiogenic macrophages and severe tumor hypoxia and,
thus, did not switch on the “angiogenic rescue program”
which is considered to be responsible for the resistance to
anti-VEGFR2 treatment.
7. Mobilization and Recruitment of
MyeloidCellsintoTumors
Substantial evidence indicates that myeloid cells and their
precursors promote neovascularization in tumors and
inﬂammatory tissues. These cells are actively recruited to the
tumor microenvironment from the bloodstream. Immune
cell traﬃcking in vivo is regulated by chemokines and by
members of the integrin, immunoglobulin superfamily, and
selectin adhesion molecule families [80, 81]. Hypoxia, as
well as chemokines and their receptors, stimulates homing of
circulating myeloid cells to tissues. When tumors encounter
low oxygen tension, they adapt by promoting expression of
genes associated with angiogenesis, metastasis, and invasion.
This transcriptional response pathway is mediated to a
large extent by the dimeric transcription factor complexes
of hypoxia-inducible factors (HIFs) [82]. HIF1 activity6 Journal of Oncology
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Figure 2: Recruitment of diverse bone marrow-derived cell populations to the tumor microenvironment and their eﬀects on tumor
progression. Tumor and stromal cells mobilize various subpopulations of tumor promoting bone marrow-derived cells to the peripheral
blood through secretion of cytokines and chemokines. Diverse chemoattractant factors promote the recruitment and inﬁltration of these
cells to the tumor microenvironment where they suppress the antitumor immunity or promote tumor angiogenesis and vasculogenesis or
raise refractoriness against anti-VEGF therapy.
promotes neovascularization by the induction of variety
of proangiogenic factors like VEGF-A, VEGFR1, PDGF-B,
bFGF, and angiopoietins that stimulate new blood vessel
formationwithinhypoxicareas.Inaddition,HIFactivityalso
regulates the expression of several chemoattractant factors,
including MCP-1, CSF-1, VEGF-A, TNFα,a n dS D F - 1 α,e a c h
of them capable to attract myeloid cells to invade hypoxic
tissues [83].
MCP-1 (or CCL2) and RANTES (or CCL5) increased
the inﬁltration of TAM into primary tumors, including
breast and ovarian carcinomas, melanoma, and glioblastoma
[84–87]. Furthermore, MCP-1 and RANTES stimulate the
secretion of matrix-degrading enzymes, such as MMP9 and
MMP12 by macrophages.
IL-8 also serves as a monocyte chemoattractant. This
chemokine is also a proangiogenic factor and an autocrine
growth factor for several human tumor cell types [88]. IL-
8 stimulates the adhesion of monocytes, which express low
levels of the IL-8 receptors CXCR1 and CXCR2, to vascular
endothelium under ﬂow conditions. These studies indicate
that IL-8 and CXCR-1/2 interactions play roles in monocyte
recruitment. Several cytokines and growth factors, including
colony stimulating factor-1 (CSF-1), VEGF, and PDGF, have
beenimplicatedintherecruitmentofmonocytesintotumors
[89–91]. CSF-1 is produced by various types of human
tumors and is a potent chemoattractant for macrophages.
Coordinated expression of CSF-1 in macrophages and
epidermal growth factor (EGF) in mammary tumor cells
resulted in increased myeloid cell invasion into mammary
tumors [91].
IL-1β, another myeloid cell cytokine, increased inﬁltra-
tion of neutrophils and macrophages in a mouse model of
corneal neovascularization. In contrast, deletion of mono-
cytes by genetic approaches or by use of toxins signiﬁcantly
suppressed IL-1β induced angiogenesis [92].
β-defensin may also serve as a recruitment factor
for myeloid lineage cells. β-defensin is a chemoattractant
factor for DC. Conjeo-Garcia and colleagues found that
the recruitment of dendritic precursor cells into tumors
required the presence of β-defensin [74]. Depletion of β-
defensin or inhibition of its receptor CCR6 using function-
blocking antibodies abolished the inﬁltration of dendritic
precursor cells into tumors. These studies indicate that
the ligand/receptor pair β-defensin/CCR6 is essential for
dendritic precursor cell recruitment.
A key role for SDF-1α in progenitor cell recruitment was
recently described [93]. Syngeneic tumors transplanted into
thrombocytopenic mice (such as Thpo-/- and Mpl-/- mice)
exhibited impaired neovascularization and reduced release
of the chemokine SDF-1α. Further studies demonstrated
that hematopoietic cytokines including soluble Kit-ligand
and thrombopoietin trigger the release of SDF-1α fromJournal of Oncology 7
platelets, which results in the mobilization of unique subset
of hemangiogenic progenitor cells (CXCR4+ VEGFR1+) to
neoangiogenic niches.
Du et al., [9] recently reported that HIF-1α, the direct
eﬀectorofhypoxia,inducesrecruitmentofdiversebonemar-
row derived subpopulations, containing Tie2+, VEGFR1+,
CD11b+,andF4/80 +,asw ellasEPCandpericyt epr ogenit ors
to promote neovascularization in glioblastoma. HIF-1α
contributed to the induction of SDF-1α in glioblastoma cells,
which in turn promoted tumor progression by recruiting
MMP9+ vascular modulatory bone marrow cells [9].
Recently Bv8, also known as prokineticin-2, was iden-
tiﬁed as a critical regulator for CD11b+Gr1+-mediated
angiogenesis. Bv8 and the related EG-VEGF were also
characterized as mitogens for speciﬁc endothelial cell types
[94]. Both Bv8 and EG-VEGF bind two highly homologous
G-protein-coupled receptors termed PKR-1 and PKR2. Bv8
expression was reported to be upregulated in CD11b+Gr1+
cells after tumor implantation [8]. Bv8 was shown to
mobilize hematopoietic cells such as CD11b+Gr1+ cells to
the blood and also stimulated the production of granulocytic
and monocytic colonies in vitro [95]. Notably, anti-Bv8
treatment of mice implanted with human tumors resulted
in a signiﬁcant reduction in tumor growth and tumor
angiogenesis. This eﬀect was associated with a reduction in
CD11b+Gr1+ mobilization from the bone marrow. Inter-
estingly G-CSF dramatically upregulates Bv8 expression [8,
96]. Hence, G-CSF produced by the tumor cells or tumor
associated ﬁbroblast may result in an upregulation of Bv8
in the BM, which, in turn, results in the induction of
diﬀerentiationofmyeloidprogenitorsandtheirmobilization
to the peripheral blood.
The immune suppressive molecule TGF-β has also been
implicated in myeloid cell functions. Experiments with a
transplantedandspontaneousmammarycarcinomademon-
stratedincreasedlevelsofTGF-β inthetumormicroenviron-
ment if the tumor cells were deﬁcient for the type II TGF-
β receptor (Tgfbr2 KO). These authors demonstrated that a
deﬁciency in the receptor resulted in an increase in CXCL5
(ENA-78) and SDF-1α in the tumor microenvironment.
Further analysis targeting the CXCL5 receptor CXCR2 with
antagonistdecreasedtherecruitmentofCD11b+Gr1+ cellsto
orthotopic transplanted Tgfbr2 KO breast adenocarcinomas
[97].
Thesestudiesdemonstratethatavarietyofinﬂammatory
stimuli can recruit diverse subsets of myeloid cells to invade
tumor tissue.
8. Conclusions
Links between chronic inﬂammation and cancer have been
recognized for several decades. Studies to understand the
recruitment of proangiogenic myeloid cells populations
and immunsuppressive MDSC and their contributions to
angiogenesis are ongoing. All these studies suggest that
several myeloid subpopulations may play roles during neo-
vascularization of tumors, mediating refractoriness to anti-
angiogenic therapies, or the escape from immune surveil-
lance (Figure 2). Much progress is needed with regards to
the characterization of markers to identify cells subsets that
have speciﬁc regulatory roles. This might further help to
understand why so many diﬀerent characterized cell types
appear to have overlapping functions.
Myeloid cells represent novel targets for therapeutic
strategies. The mobilization and recruitment of myeloid cells
by the tumor deﬁnes myeloid cells as a potential delivery
system to target the tumor microenvironment. One such
approach was recently shown using TEM. Mice transplanted
withTEM expressinginterferonα(IFN-α),apotent cytokine
withangiostaticandanti-proliferativeactivity[98]under the
Tie2 promotor,inhibitedtumorprogressioninseveraltumor
models [99]. Targeting cytokines and cytotoxic proteins
to tumors by means of gene-modiﬁed myeloid cells thus
represents a promising strategy to treat cancer [100].
In contrast, the tumor promoting properties of myeloid
cells deﬁne these cells as putative targets for anticancer
therapies. Anti-angiogenic agents were already described to
bethemosteﬃcaciouswhencombinedwithcytotoxicagents
and/or therapies targeted towards ablating myeloid cells [5,
101]. Furthermore, suppression of myeloid cell recruitment
to the tumor microenvironment oﬀers a new strategy
to inhibit tumor neovascularization, while stimulation of
homing may promote tissue recovery from ischemia.
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